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Abstract. 
 
Protein kinase A (PKA) and the nuclear
A-kinase–anchoring protein AKAP95 have previously 
been shown to localize in separate compartments in in-
terphase but associate at mitosis. We demonstrate here 
a role for the mitotic AKAP95–PKA complex. In HeLa 
cells, AKAP95 is associated with the nuclear matrix in 
interphase and redistributes mostly into a chromatin 
fraction at mitosis. In a cytosolic extract derived from 
 
mitotic cells, AKAP95 recruits the RII
 
a
 
 regulatory sub-
unit of PKA onto chromatin. Intranuclear immuno-
 
blocking of AKAP95 inhibits chromosome condensation 
at mitosis and in mitotic extract in a PKA-independent 
manner. Immunodepletion of AKAP95 from the ex-
tract or immunoblocking of AKAP95 at metaphase in-
duces premature chromatin decondensation. Conden-
sation is restored in vitro by a recombinant AKAP95 
fragment comprising the 306–carboxy-terminal amino 
acids of the protein. Maintenance of condensed chro-
matin requires PKA binding to chromatin-associated 
AKAP95 and cAMP signaling through PKA. Chroma-
tin-associated AKAP95 interacts with Eg7, the human 
 
homologue of 
 
Xenopus
 
 pEg7, a component of the 13S 
condensin complex. Moreover, immunoblocking nu-
clear AKAP95 inhibits the recruitment of Eg7 to chro-
matin in vitro. We propose that AKAP95 is a multiva-
lent molecule that in addition to anchoring a cAMP/
PKA–signaling complex onto chromosomes, plays a 
role in regulating chromosome structure at mitosis.
Key words: AKAP • cAMP • chromosome condensa-
tion • mitosis • PKA
 
P
 
ROPER
 
 packaging of DNA into chromosomes is an
essential process in preparation for mitosis. Chro-
 
mosome condensation at mitosis requires DNA
topoisomerase II (Adachi et al., 1991) and a family of
 
proteins of highly conserved ATPases called SMCs
 
1
 
(structural maintenance of chromosomes) (Hirano and
Mitchison, 1994; Saitoh et al., 1994; Hirano et al., 1997).
Evidence that SMCs promote chromosome condensation
was provided by the purification of 
 
Xenopus
 
 8S and 13S
multiprotein complexes, termed condensins (Hirano et al.,
1997), and the demonstration that two of these proteins
are required for chromosome condensation and mainte-
nance of condensed chromatin (Hirano and Mitchison,
1994). Another component of the 13S condensin complex,
pEg7, was also recently shown to be implicated in mitotic
chromosome condensation in vitro (Cubizolles et al.,
1998).
cAMP-dependent protein kinase A (PKA) has been
proposed to be a negative regulator of mitosis. PKA activ-
ity oscillates in cycling 
 
Xenopus
 
 egg extracts (Grieco et al.,
1994). Onset of mitosis correlates with a decrease in
cAMP level and PKA activity, whereas cAMP level and
PKA activity rise during metaphase to peak at early inter-
phase (Grieco et al., 1996). Consistent with this finding,
downregulation of PKA mediated by microinjection of the
PKA inhibitor PKI was shown together with activation of
cyclin-dependent kinase 1 (CDK1) to be required for mi-
totic nuclear envelope disassembly and chromatin conden-
sation in cultured mammalian cells (Lamb et al., 1991). In
contrast, PKA activation is necessary for nuclear reassem-
bly upon exit from mitosis (Grieco et al., 1996). These
results suggest a requirement for a downregulation of
cAMP/PKA signaling for entry into mitosis, but they do
not explain the gradual rise in PKA activity during mitosis.
Biological effects of cAMP are mainly mediated by
PKA types I and II in eukaryotic cells. The PKA type II
holoenzyme complex consists of two catalytic (C) and two
regulatory (RII
 
a
 
 or RII
 
b
 
) subunits, which modulate the
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catalytic activity of PKA by binding and inactivating C
(Scott, 1991). PKA is activated by binding of two cAMP
molecules to each R subunit that promotes release of the
C subunits from the R–cAMP complex. Active C subunits
phosphorylate specific substrates and can be translocated
to the nucleus, where they play a role in gene activation
(Riabowol et al., 1988).
The specificity of cellular and nuclear responses to
cAMP is mediated by targeting of the RII subunit of PKA
to discrete subcellular loci through associations with
A-kinase–anchoring proteins or AKAPs (Colledge and
Scott, 1999). A 95-kD AKAP, designated AKAP95, has
been cloned and characterized in the rat (Coghlan et al.,
1994) and human (Eide et al., 1998). AKAP95 has been lo-
calized exclusively in the nucleus of interphase rat and hu-
man fibroblasts (Coghlan et al., 1994; Eide et al., 1998);
however, as no RII
 
a
 
 has been detected in interphase nu-
clei (Eide et al., 1998), the role of AKAP95 in the nucleus
remains elusive. At mitosis, AKAP95 interacts with RII
 
a
 
apparently in the vicinity of the metaphase plate (Eide et
al., 1998). These observations suggest that interaction be-
tween AKAP95 and RII
 
a
 
 may be cell cycle–regulated, but
the significance of the AKAP95–RII
 
a
 
 complex at mitosis
remains unknown.
We demonstrate here in in vivo and in vitro immuno-
blocking and rescue experiments the formation of an
AKAP95–PKA signaling complex onto mitotic chromo-
somes, and a role of AKAP95 in chromatin condensation
and maintenance of condensed chromosomes during mito-
sis. The latter process also requires cAMP/PKA signaling
and anchoring of PKA to chromatin by AKAP95. The
data also suggest that one function of AKAP95 is to pro-
mote the recruitment of components of the condensin
complex onto chromatin. The results argue towards a criti-
cal role of AKAP95 in the regulation of chromatin struc-
ture at mitosis and provide a functional significance for in-
creasing PKA activity during mitosis.
 
Materials and Methods
 
Buffers, Reagents, and Antibodies
 
Nuclear isolation buffer (buffer N) consisted of 10 mM Hepes, pH 7.5,
2 mM MgCl
 
2
 
, 250 mM sucrose, 25 mM KCl, 1 mM DTT, 1 mM PMSF, and
10 
 
m
 
g/ml each of aprotinin, leupeptin, and pepstatin A. Cell lysis buffer
consisted of 20 mM Hepes, pH 8.2, 5 mM MgCl
 
2
 
, 10 mM EDTA, 1 mM
DTT, and 20 
 
m
 
g/ml cytochalasin B and protease inhibitors. A GST-
AKAP95 fragment covering amino acids 387–692 and including the RII-
binding domain of human AKAP95 (designated GST-AKAP95
 
D
 
1-386)
was described previously (Eide et al., 1998; see Fig. 5 C). A synthetic pep-
tide derived from the AKAP Ht31 was described previously and con-
tained the amphipathic helix structure of Ht31 required for RII binding
(Carr et al., 1991); thus, Ht31 was used as a specific inhibitor of AKAP–
RII interaction. Control Ht31-P peptides corresponded to Ht31 with two
isoleucine residues mutated to prolines, disrupting the amphipathic helix
structure of AKAPs (Carr et al., 1991). Affinity-purified rabbit polyclonal
antibodies against AKAP95 (Upstate Biotechnology Inc.) were described
elsewhere (Coghlan et al., 1994; Eide et al., 1998). Two novel mAbs
against human AKAP95 (mAb36 and mAb47) were developed in con-
junction with Transduction Laboratories. Each mAb was produced by im-
munizing mice with the GST-AKAP95
 
D
 
1-386 fusion peptide. Anti–
human RII
 
a
 
 mAbs (Transduction Laboratories) were described earlier
(Eide et al., 1998). Affinity-purified rabbit antibodies against human
lamin B receptor (LBR) or heterochromatin protein 1
 
a
 
, rabbit antiserum
against a peptide of human lamin B, and human anti–lamin B autoanti-
bodies (gifts from J.-C. Courvalin, Institut Jacques Monod, Paris, France)
 
were described previously (Chaudhary and Courvalin, 1993; Collas et al.,
1996; Buendia and Courvalin, 1997; Minc et al., 1999). Anti–human Eg7
polyclonal antibodies were generated by immunizing rabbits with a pep-
tide comprising the last 15 amino acids of human Eg7 (KTTPILRASAR-
RHRS) (Cubizolles et al., 1998).
 
Cell Synchronization and Microinjection
 
HeLa cells were grown in EMEM medium (GIBCO BRL) as described in
Eide et al. (1998). For microinjections, cells were synchronized in S phase
by a double thymidine (2.5 mM) block (Keryer et al., 1998). Cells were
synchronized in M phase by subsequent exposure to 1 
 
m
 
M nocodazole for
18 h (Eide et al., 1998). Mitotic indexes were typically 
 
z
 
95%.
For nuclear microinjections, HeLa cells were plated onto glass cover-
slips at 10
 
6
 
 cells per 28-cm
 
2
 
 dish and synchronized in S phase by double
thymidine block. Nuclei were microinjected with 25–50 pl of solution us-
ing a Narishige micromanipulator and picoinjector. Injection solution con-
sisted of EMEM containing 10 
 
m
 
g/ml of a 150-kD FITC-dextran (Sigma
Chemical Co.) to visualize the injections. Nuclei were injected with either
2–5 pg affinity-purified anti–AKAP95 polyclonal antibodies (at 
 
z
 
0.1 mg/ml
IgG), mAb36 (diluted 1/10), 2–5 pg preimmune IgGs (at 
 
z
 
0.1 mg/ml), or
 
z
 
250 pg GST-AKAP95
 
D
 
1-386 peptide together with anti–AKAP95 anti-
bodies. Inhibitors, antagonists, or catalytic peptides were injected at con-
centrations indicated in Results. Successful nuclear injections were as-
sessed by retention of the FITC-dextran within the nucleus 1 h after
injection (see Results). After a resting period of 6 h, injected cells were
synchronized in M phase with 1 
 
m
 
M nocodazole. Mitotic cells were micro-
injected as described above while arrested in M phase with nocodazole.
Injected cells remained in nocodazole for up to 2 h after injection during
the period of observation.
 
Mitotic and Interphase Cell Extracts
 
Mitotic HeLa cells were washed once in ice-cold PBS, once in 20 vol of
ice-cold lysis buffer, and packed at 800 
 
g
 
 for 10 min. The cell pellet was re-
suspended in 1 vol of lysis buffer and incubated for 30 min on ice. Cells
were homogenized by a 2
 
3
 
 2-min sonication on ice and the lysate was cen-
trifuged at 10,000 
 
g
 
 for 15 min at 4
 
8
 
C. The supernatant was cleared at
200,000 
 
g
 
 for 3 h at 4
 
8
 
C in a Beckman SW55 rotor. The clear supernatant
(mitotic cytosolic extract) was aliquoted, frozen in liquid nitrogen, and
stored at 
 
2
 
80
 
8
 
C. Protein concentration of the extract was usually 
 
z
 
15 mg/
ml. Interphase cytosolic extracts were prepared as above from unsynchro-
nized HeLa cells (95–98% in interphase) except that EDTA was omitted
from the cell lysis buffer.
 
Preparation of Nuclei and Chromatin
 
Confluent unsynchronized HeLa cells were harvested, washed in PBS,
sedimented at 400 
 
g
 
, and resuspended in 20 vol of ice-cold buffer N con-
taining 10 
 
m
 
g/ml cytochalasin B. After a 30-min incubation on ice, cells
were homogenized on ice by 140–170 strokes of a tight fitting (B-type)
glass pestle in a 7-ml homogenizer. Nuclei were sedimented at 400 
 
g
 
 for 10
min at 4
 
8
 
C and washed twice by resuspending in buffer N and centrifuging
as above. Essentially, all nuclei recovered were morphologically intact, as
judged by phase-contrast microscopy and labeling with 10 
 
m
 
g/ml FITC-
conjugated ConA (data not shown) (Collas, 1999). Nuclei were used fresh
or frozen at 
 
2
 
80
 
8
 
C in buffer N containing 70% glycerol. High salt (2 M
NaCl)–extracted nuclear matrices were prepared from purified nuclei as
described previously (Reyes et al., 1997). Matrices were solubilized in 8 M
urea/10 mM Tris-HCl, pH 8.0.
To prepare interphase chromatin, 10
 
8
 
 HeLa nuclei suspended in 200 
 
m
 
l
buffer N containing 1% Triton X-100 were incubated with 5 U of micro-
coccal nuclease (Sigma Chemical Co.) at 37
 
8
 
C for 5 min. Digestion was
terminated by adding EDTA to 5 mM and the mixture was centrifuged at
10,000 
 
g
 
 for 5 min. The supernatant (S1) was collected and the pellet was
resuspended in 2 mM EDTA and incubated for 15 min at 4
 
8
 
C. After sedi-
mentation as above, the supernatant (S2) was combined with S1 to yield
the chromatin fraction, proteins were precipitated with 10% TCA and dis-
solved in SDS sample buffer. To solubilize mitotic condensed chromatin,
mitotic cell lysates were centrifuged at 10,000 
 
g
 
 for 10 min. The pellet was
resuspended in 500 
 
m
 
l buffer and sedimented at 1,000 
 
g
 
 for 20 min in a
swingout rotor (Eppendorf) through a 1-M sucrose cushion made in
buffer N. Mitotic chromosomes were recovered from the pellet. This pel-
let was extracted with 1% Triton X-100 at 4
 
8
 
C for 30 min, sedimented at
15,000 
 
g
 
 for 15 min, and the detergent-insoluble fraction was digested with
5 U/ml micrococcal nuclease at 37
 
8
 
C for 5 min. After sedimentation as 
Collas et al. 
 
AKAP95 Function in Chromosome Condensation
 
1169
 
above, proteins of the supernatant (soluble chromatin) were precipitated
in 10% TCA and dissolved in SDS-sample buffer.
 
Loading of Nuclei with Anti–AKAP95 Antibodies
 
Purified HeLa cell nuclei (2,000 nuclei/
 
m
 
l) were permeabilized in 500 
 
m
 
l
buffer N containing 0.75 
 
m
 
g/ml lysolecithin for 15 min at room tempera-
ture. Excess lysolecithin was quenched by adding 1 ml of 3% BSA made
in buffer N and incubating for 5 min on ice, before sedimenting the nuclei
and washing once in buffer N. Nuclei were resuspended at 2,000 nuclei/
 
m
 
l
in 100 
 
m
 
l buffer N containing affinity-purified anti–AKAP95 antibodies
(1:40 dilution; 2.5 
 
m
 
g) or 2.5 
 
m
 
g of preimmune rabbit IgGs. After a 1-h in-
cubation on ice with gentle agitation, nuclei were sedimented at 500 
 
g
 
through 1 M sucrose for 20 min and held in buffer N on ice until use. Anti-
body loading of nuclei was verified by immunofluorescence. AKAP95 was
not proteolyzed during permeabilization and antibody loading proce-
dures, and lysolecithin-treatment of nuclei did not affect nuclear envelope
disassembly or chromatin condensation in mitotic extract (data not
shown).
 
Nuclear Disassembly and Chromatin
Condensation Assay
 
A nuclear disassembly/chromatin condensation reaction consisted of 20 
 
m
 
l
mitotic extract, 1 
 
m
 
l nuclear suspension (
 
z
 
2 
 
3 
 
10
 
4
 
 nuclei), and 0.6 
 
m
 
l of an
ATP-generating system (1 mM ATP, 10 mM creatine phosphate, 25 
 
m
 
g/ml
creatine kinase; Collas, 1998). The reaction was started by addition of the
ATP-generating system and allowed to proceed at 30
 
8
 
C for up to 2 h. The
extract supported nuclear envelope disassembly and chromatin condensa-
tion without apoptotic proteolysis of nuclear envelope proteins or DNA
degradation (data not shown; see Lazebnik et al., 1993; Duband-Goulet
et al., 1998). Chromatin condensation was monitored by after staining
samples with 0.1 
 
m
 
g/ml Hoechst 33342. Chromatin was considered to con-
dense when it acquired an irregular and compact morphology sometimes
with distinct chromosomes or chromosome fragments. In some instances,
extracts were preincubated with inhibitors for 30 min on ice before adding
nuclei and the ATP-generating system. Percent chromatin condensation
was calculated as the ratio of condensed chromatin masses per number of
nuclei examined. For biochemical analyses, condensed chromatin was sed-
imented at 1,000 
 
g
 
 through 1 M sucrose as described above and recovered
from the pellet.
 
Premature Chromatin Decondensation Assay
 
HeLa chromatin condensed in mitotic extract was recovered by sedimen-
tation at 1,000 
 
g
 
 through 1 M sucrose, washed by resuspension and sedi-
mentation in lysis buffer, and incubated for up to 2 h in fresh mitotic ex-
tract, either intact or immunodepleted of AKAP95 or RII
 
a
 
. In some
experiments, this extract contained antibodies or inhibitors. DNA was la-
beled with Hoechst and examined as above. Premature chromatin decon-
densation (PCD) referred to swelling of the chromatin into ovoid or
spherical objects, with no discernible chromosomes. Kinetics of PCD was
evaluated by measurement of the proportion of chromatin masses under-
going decondensation at regular time intervals.
 
Histone H1 Kinase Assay
 
5 
 
m
 
l of HeLa cytosolic extract was mixed with 5 
 
m
 
l of a 2
 
3
 
 histone kinase
buffer (160 mM 
 
b
 
-glycerophosphate, 20 mM EGTA, 30 mM MgCl
 
2
 
, 2 mM
DTT, 20 
 
m
 
g/ml each of aprotinin, leupeptin, and pepstatin A, and 100 nM
PKI). The kinase reaction was initiated by addition of 10 
 
m
 
l of a cocktail
containing 2.5 mg/ml histone H1, 0.7 mM ATP, and 50 
 
m
 
Ci of 
 
g
 
-[
 
32
 
P]ATP.
The reaction was carried out at room temperature for 15 min and stopped
by addition of 15 
 
m
 
l of 2
 
3
 
 SDS loading buffer and boiling. Proteins were
resolved by 15% SDS-PAGE, the gel was dried, and phosphorylation of
histone H1 was visualized by autoradiography.
 
Immunological Procedures
 
Immunoblotting of nuclei, chromatin, and reaction supernatants was per-
formed as described (Collas et al., 1996) using the following antibodies:
rabbit anti-AKAP95 (1:250 dilution), rabbit anti-lamin B (1,000), anti-
LBR (1:500), RII
 
a
 
 mAb (1:250), anti-Eg7 (1:500), and HRP-conjugated
secondary antibodies. Blots were revealed with chloronaphtol/hydrogen
peroxide (Collas et al., 1996) or by enhanced chemiluminescence (Amer-
 
sham). For immunoprecipitations, whole mitotic or interphase cells (as in-
dicated) were sonicated twice for 2 min on ice in immunoprecipitation
(IP) buffer (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 1% Triton X-100, and
protease inhibitors), and the lysate was centrifuged at 15,000 
 
g
 
 for 15 min.
The supernatant was precleared with protein A/G agarose (1:25 dilution)
at 4
 
8
 
C for 1 h. Immunoprecipitations were carried out with relevant anti-
bodies (anti–RII
 
a
 
 mAb, anti–AKAP95 polyclonal, and anti-Eg7, each
at a 1:50 dilution) from the supernatant at room temperature for 2.5 h,
followed by incubation with protein A/G agarose (1:25 dilution) for 1.5 h
and centrifugation at 4,000 
 
g
 
 for 10 min. Immune complexes were washed
three times in IP buffer and proteins were eluted in 2
 
3
 
 SDS boiling
sample buffer. RII
 
a
 
 was also immunoprecipitated from mitotic extract,
or chromatin, or reaction supernatant fractions diluted 10
 
3
 
 in IP buffer
and sonicated (chromatin fraction only). AKAP95 or RII
 
a
 
 was also im-
munodepleted from undiluted cytosolic extracts using affinity-purified
anti–AKAP95 antibodies or anti–RII
 
a
 
 mAbs at a 1:50 dilution. For immu-
nofluorescence analysis (Collas et al., 1996), cells, nuclei, or condensed
chromatin masses were settled onto poly-
 
L
 
-lysine–coated coverslips, fixed
with 3% paraformaldehyde, permeabilized with 0.5% (cells) or 0.1% (nu-
clei) Triton X-100, and proteins were blocked with 2% BSA in PBS/0.01%
Tween 20 (PBST). Primary antibodies (anti–AKAP95 polyclonal, anti-
LBR, anti–RII
 
a
 
 mAb, anti–lamin B human autoantibody) and secondary
antibodies were used at a 1:100 dilution. DNA was stained with 0.1 
 
m
 
g/ml
Hoechst 33342. Observations were made on an Olympus AX70 epifluo-
rescence microscope using a 100
 
3
 
 objective, and photographs were taken
with a Photonic Science CCD camera and OpenLab software (Improvi-
sion Co.).
 
Results
 
Subcellular Distribution of Human AKAP95 during the 
Cell Cycle
 
The subcellular localization of human AKAP95 was exam-
ined throughout the HeLa cell cycle. Immunofluorescence
analysis using an affinity-purified anti–AKAP95 antibody
confirmed that AKAP95 was exclusively nuclear in inter-
phase, colocalized with DNA, and was excluded from nu-
cleoli (Fig. 1 A). As early as prometaphase and until telo-
phase, AKAP95 staining colocalized with chromosomes
over a diffuse cytoplasmic labeling (Fig. 1 A). In late telo-
phase/interphase, AKAP95 labeling became excluded
from the cytoplasm and restricted to the daughter nuclei
(Fig. 1 A). Similar results were obtained with two newly
developed anti–AKAP95 mAbs, mAb36 and mAb47, and
in human 293T fibroblasts with all three antibodies (data
not shown).
Immunoblotting analysis of AKAP95 revealed similar
levels of AKAP95 in whole interphase and mitotic cell ly-
sates (Fig. 1 B). Fractionation of interphase and mitotic
cells confirmed that AKAP95 was exclusively nuclear in
interphase (Fig. 1 C). At mitosis, 
 
z
 
75% of AKAP95 co-
fractionated with chromatin, whereas 
 
z
 
25% was detected
in a 200,000-
 
g
 
 supernatant fraction (Fig. 1 C, cytosol). No
AKAP95 was detected in membrane fractions of inter-
phase or mitotic cells (Fig. 1 C). Furthermore, fraction-
ation of purified HeLa nuclei into chromatin and high
salt–extracted nuclear matrices revealed that 
 
z
 
80% of
AKAP95 partitioned with the matrix, whereas 
 
z
 
20% co-
fractionated with chromatin (Fig. 1 D). Thus, AKAP95
is restricted to the nuclei of interphase cells, where it as-
sociates primarily with the nuclear matrix. At mitosis,
AKAP95 redistributes into a major chromatin-associated
fraction and a minor soluble pool. Upon nuclear reassem-
bly at the end of mitosis, AKAP95 is sequestered into the
daughter nuclei where it re-acquires an interphase distri-
bution. 
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AKAP95 Associates with the RII
 
a
 
 Regulatory Subunit 
of PKA at Mitosis and in the Mitotic Extract
 
Association of AKAP95 with RII
 
a
 
 in interphase and mito-
sis was investigated in dual immunofluorescence and im-
munoprecipitation experiments. In interphase, AKAP95
labeling was clearly distinct from the cytoplasmic stain-
ing of RII
 
a
 
 (Fig. 2 A, right cell in all panels). At mitosis,
RII
 
a
 
 exhibited a more uniform cytoplasmic labeling that
mostly overlapped with that of AKAP95 (Fig. 2 A, left cell
in all panels). Although both AKAP95 and RII
 
a
 
 were de-
tected by immunoblotting in interphase whole cell lysates
(Fig. 2 B, left), immunoprecipitation of RII
 
a
 
 from such ly-
sates did not coprecipitate AKAP95 in interphase, but did
coprecipitate AKAP95 at mitosis (Fig. 2 B, right). Immu-
noprecipitation of RII
 
a
 
 also coprecipitated AKAP95 from
both a mitotic cytosolic fraction and from mitotic chroma-
 
tin solubilized by micrococcal nuclease digestion (Fig. 2
C). This illustrates the assembly of both soluble and chro-
matin-associated AKAP95–RIIa complexes at mitosis.
The dynamics of formation of the chromatin-associated
mitotic AKAP95–RIIa complex was investigated using a
cytosolic extract prepared from mitotic HeLa cells. The
extract supports disassembly of exogenous purified inter-
phase HeLa nuclei, including nuclear envelope breakdown
and chromatin condensation (see Materials and Meth-
ods). Immunofluorescence and immunoblotting analysis
of input nuclei and condensed chromatin showed that
AKAP95 was associated with the condensing chromatin
(Fig. 3 A, a-AKAP95, and B, top panel). As in vivo, a mi-
nor portion of AKAP95 was also released into the cytosol
during chromatin condensation (data not shown). Con-
comitantly, RIIa, undetected in input interphase nuclei,
was recruited from the extract onto the chromatin surface
where it colocalized and cofractionated with AKAP95
(Fig. 3 A, a-RIIa and Merge, and B, bottom panel). Fur-
thermore, immunoprecipitation of RIIa from condensed
chromatin coprecipitated AKAP95 (Fig. 3 C), illustrating
the formation of a chromatin-associated AKAP95–RIIa
complex during chromatin condensation in vitro. It is
noteworthy that association of AKAP95 with chromatin
also occurred in mitotic extract immunodepleted of RIIa
(data not shown), indicating that mitotic redistribution of
AKAP95 is independent of RIIa.
Altogether, these results indicate that in mitotic extract,
nuclear AKAP95 is redistributed and primarily associates
with condensing chromosomes in an RIIa-independent
manner. Concomitantly, AKAP95 recruits RIIa from a cy-
tosolic pool onto chromatin. Thus, one function of chro-
matin-associated AKAP95 at mitosis is to target PKA, via
RIIa, to condensing chromosomes.
Mitotic Chromosome Condensation Requires 
Functional AKAP95
The functional significance of the chromatin-associated
AKAP95–RIIa complex was first investigated using the
mitotic extract. To this end, we attempted to block the
function of nuclear AKAP95 by introducing affinity-puri-
fied anti–AKAP95 antibodies (or control preimmune rab-
bit IgGs) into purified HeLa nuclei as described in Materi-
als and Methods. Antibody-loaded nuclei (Fig. 4 A, Input)
were exposed to mitotic extract and nuclear disassembly
assessed after 2 h by DNA staining and immunofluores-
cence analysis using anti–lamin B and anti–LBR antibod-
ies. Fig. 4 A shows that anti–AKAP95 antibodies, but not
preimmune IgGs, inhibited chromatin condensation al-
though nuclear envelope disassembly took place as judged
by the absence of lamin B or LBR labeling. Inhibition
of chromatin condensation occurred with most (z90%)
chromatin masses examined (see Fig. 4 C, Poly) and was
reproduced by mAb36, whereas mAb47 was little effective
(Fig. 4 C). Inhibition of chromatin condensation was spe-
cific for anti–AKAP95 antibodies since it did not occur
with the following: anti–AKAP95 antibodies introduced
into nuclei with 0.1 mg/ml of the GST-AKAP95D1-386
peptide (Fig. 4 B) used to generate the antibodies (Fig. 4
C, Poly 1 AKAP95, mAb36 1 AKAP95); and affinity-
purified polyclonal antibodies against heterochromatin
Figure 1. Subcellular and subnuclear localization of AKAP95 in
HeLa cells. (A) The distribution of AKAP95 during the HeLa
cell cycle was examined by immunofluorescence analysis of un-
synchronized cells using an affinity-purified polyclonal anti–
AKAP95 antibody. DNA (insets) was labeled with Hoechst
33342. Bar, 10 mm. (B) Interphase (I) and mitotic (M) HeLa cells
(107 cells each) were dissolved in SDS-sample buffer, proteins
separated by SDS-PAGE, and immunoblotted using the affinity-
purified anti–AKAP95 antibody. (C) Interphase and mitotic
HeLa cells (107 and 5 3 107, respectively) were fractionated into
nuclei or chromatin, cytosol, and cytoplasmic membranes, and
proteins of each fraction were immunoblotted using anti–
AKAP95 antibodies. Relative amounts of AKAP95 in each frac-
tion were determined by densitometric analysis of duplicate
blots. (D) Purified HeLa nuclei (108) were fractionated into chro-
matin and high salt–extracted nuclear matrices, proteins were im-
munoblotted using anti–AKAP95 antibodies, and duplicate blots
analyzed by densitometry.Collas et al. AKAP95 Function in Chromosome Condensation 1171
proteins HP1a (Fig. 4 C), HP1b, or HP1g (not shown)
(Minc et al., 1999).
Preincubation of anti–AKAP95 antibodies in the extract
or immunodepletion of soluble AKAP95 did not inhibit
condensation (Fig. 4 C). This illustrates a role for nuclear
rather than cytosolic AKAP95 in chromatin condensation.
Additionally, loading nuclei with anti–AKAP95 antibod-
ies did not block the recruitment of RIIa onto the chroma-
tin, as judged by immunofluorescence and immunoblot-
ting analyses of condensed chromatin (data not shown).
This argues that inhibition of chromatin condensation with
anti–AKAP95 antibodies does not result from inhibition
of the PKA-anchoring activity of AKAP95.
To determine whether inhibiting nuclear AKAP95 func-
tion in vivo affected mitotic chromosome condensation,
nuclei of HeLa cells synchronized in S phase by a double
thymidine block were microinjected with z2–5 pg of anti–
AKAP95 polyclonal antibodies or mAb36, each with or
without 250 pg of competitor GST-AKAP95D1-386 pep-
tide, or with preimmune IgGs. Successful nuclear injec-
tions were verified by coinjection of a 150-kD FITC-dex-
tran and scored by retention of the dextran within the
nuclei 1 h after injection (Fig. 5 A, a, green). Injected cells
were released from the thymidine block, exposed to 1 mM
nocodazole, and the proportion of cells arrested at mitosis
was determined after 17 h. A fraction of injected cells was
also analyzed by immunofluorescence using antibodies
against LBR, a marker of the inner nuclear membrane.
Fig. 5 shows that, after nocodazole treatment, cells in-
jected with anti–AKAP95 antibodies did not undergo
chromosome condensation, as shown by the absence of de-
tectable metaphase chromosomes under bright field mi-
croscopy (Fig. 5 A, c and d) and after DNA staining in
most cells (Fig. 5 C), and by mitotic indexes of 15–20%
(Fig. 5 B). In contrast, preimmune IgGs or anti–AKAP95
antibodies injected with GST-AKAP95D1-386 did not pre-
Figure 3. Association of the RIIa regulatory subunit of PKA with AKAP95 during chromatin condensation. (A) Purified HeLa nuclei
were disassembled in mitotic extract and double-labeled with anti–AKAP95 and anti–RIIa antibodies at indicated time points. Arrows
in merged images point to initial sites of RIIa accumulation on the chromatin. Bar, 10 mm. (B) Input nuclei and condensed chromatin
(after 2 h in the extract as in A) were immunoblotted using anti–AKAP95 and anti–RIIa antibodies. (C) Immunoprecipitation of RIIa
from lysates of input nuclei (N) or condensed chromatin (Ch). Immune complexes were immunoblotted using anti-AKAP95 antibodies.
HC, IgG heavy IgG chain.
Figure 2. Dynamic association of AKAP95 with the RIIa regula-
tory subunit of PKA in HeLa cells. (A) Double immunofluores-
cence analysis of AKAP95 and RIIa using affinity-purified anti–
AKAP95 antibodies and an mAb against human RIIa. DNA was
labeled with Hoechst 33342. In each panel, the left cell is in mito-
sis, whereas the right cell is in interphase. Bar, 10 mm. (B, left two
panels) Immunoblotting of AKAP95 and RIIa in interphase (I)
cells using antibodies described in A. (right) Coimmunoprecipi-
tation of AKAP95 with RIIa from mitotic (M) but not interphase
(I) cells. Cells were lysed by sonication, the lysate was cleared at
15,000 g, and RIIa was immunoprecipitated (IP) from the super-
natant using anti–RIIa mAbs. Precipitates were immunoblotted
with anti–AKAP95 antibodies. (C) Anti-RIIa immunoprecipita-
tion from interphase nuclei (N), mitotic condensed chromatin
(Ch), or mitotic extract (Cyt). Precipitates were immunoblotted
with anti–AKAP95 antibodies. HC, IgG heavy chain.The Journal of Cell Biology, Volume 147, 1999 1172
vent chromosomes from forming a metaphase plate (Fig. 5
A, b and e, and B; see Table I). In addition, despite the
lack of chromosome condensation in antibody-injected
cells, the release of FITC-dextran from the nucleus into
the cytoplasm of these cells after nocodazole treatment
(Fig. 5 A, c and d, green) argued that the nuclear envelope
was disassembled. This was verified by immunofluores-
cence analysis of LBR (Fig. 5 C). Breakdown of the nu-
clear envelope implies that immunoblocking of nuclear
AKAP95 does not prevent entry into mitosis per se, but
rather affects chromosome structure at this stage of the
cell cycle. However, it should be noted that microinjection
of a 25-fold higher concentration of anti–AKAP95 anti-
bodies blocked nuclear envelope breakdown in the major-
ity of injected cells (data not shown).
Mitotic Chromosome Condensation Does Not Require 
Anchoring of PKA to AKAP95 nor PKA Activity
The recruitment of RIIa by AKAP95 onto condensing
chromatin led us to determine whether the putative role of
AKAP95 in chromatin condensation required association
with RIIa and anchoring of PKA. To this end, the RII-
anchoring inhibitor peptide Ht31 (500 nM) was preincu-
bated in mitotic extract before adding nuclei. Chroma-
tin condensed to the same extent with Ht31 and control
Ht31-P peptides that do not compete binding of RII to
AKAPs (data not shown). Thus, the role of AKAP95 in
chromosome condensation in vitro is independent of its
RII-anchoring function. Furthermore, neither chromatin
condensation nor nuclear envelope disassembly was af-
fected by inhibiting PKA activity in the extract with 1 mM
of the PKA inhibitor PKI, or by downregulating cAMP
signaling with 100 mM of the cAMP antagonists Rp-8-Br-
cAMPS or Rp-8-CPT-cAMPS (data not shown). Thus,
chromosome condensation in mitotic extract does not re-
quire cAMP signaling or PKA activity.
The effects of disrupting AKAP-RII anchoring and
downregulating cAMP/PKA signaling on chromosome
condensation at mitosis were investigated by microinject-
ing nuclei of interphase HeLa cells with 50 nM Ht31, 50 nM
Ht31-P, 10 nM PKI, or 10 mM Rp-8-Br-cAMPS, and as-
sessing mitotic indexes after nocodazole treatment as done
previously after immunoblocking of AKAP95. As shown
in Table I, neither reagent inhibited nuclear envelope
breakdown (data not shown) nor chromosome condensa-
tion, as judged by mitotic indexes of 79–90%. Therefore,
disruption of AKAP95-RII anchoring or cAMP/PKA inhi-
bition does not impair mitotic chromosome condensation.
AKAP95 Function Is Required to Maintain 
Chromosomes Condensed during Mitosis
Although chromatin condensation occurred normally in
the mitotic extract containing anti–AKAP95 antibodies,
we consistently observed a phase of decondensation of the
chromatin upon prolonged (.4 h) incubation in the ex-
tract (data not shown). This raised the hypothesis that in-
hibition of AKAP95 might affect the morphology of the
condensed chromatin. To test this possibility, chromatin
was allowed to condense for 2 h in mitotic extract, anti–
AKAP95 antibodies were added (1:50 dilution) and chro-
matin morphology was examined by DNA staining after
another 2 h of incubation. Chromatin decondensation was
observed in extract containing anti–AKAP95 antibodies
(Fig. 6 A, 1a-AKAP95), but not in the extract containing
preimmune IgGs or anti–AKAP95 antibodies together
with 0.1 mg/ml of GST-AKAP95D1-386 competitor pep-
tide (Fig. 6 A). Thus, immunoblocking AKAP95 in the ex-
tract prevented the chromatin from remaining in a con-
Figure 4. Anti–AKAP95 antibodies introduced into nuclei in-
hibit chromatin condensation in mitotic extract. (A) HeLa nuclei
were loaded with either affinity-purified anti–AKAP95 antibod-
ies (1a-AKAP95) or preimmune IgGs (1IgGs) and incubated
for 2 h in a cytosolic extract prepared from mitotic HeLa cells.
Aliquots of extracts were immunofluorescently labeled with hu-
man anti–lamin B (a-LB) and rabbit anti–LBR (a-LBR) anti-
bodies. DNA was stained with Hoechst 33342. Note the lack of
chromatin condensation with anti–AKAP95 antibodies (middle).
(B) Schematic representation of full-length human AKAP95
(top; Eide et al., 1998) and of the GST-AKAP95D1-386 peptide
(bottom). (C) HeLa nuclei were loaded with either preimmune
IgGs (IgG), affinity-purified anti–AKAP95 antibodies (Poly)
alone, or together with a competitor GST-AKAP95D1-386 pep-
tide (Poly 1 AKAP95), mAb36 alone or with GST-AKAPD951-
386 (mAb36 1 AKAP95), mAb47 or affinity-purified anti–HP1a
antibodies (a-HP1a). Nuclei were incubated in mitotic extract
for 2 h as in A, the DNA was stained, and proportions (percent 6
SD) of decondensed (open bars) and condensed (filled bars)
chromatin masses determined. Alternatively, untreated nuclei
were incubated in mitotic extract containing affinity-purified
anti–AKAP95 antibodies or immunodepleted of soluble
AKAP95, and proportions of decondensed and condensed chro-
matin masses were determined (right two data sets).Collas et al. AKAP95 Function in Chromosome Condensation 1173
densed form. To determine whether immunodepletion of
AKAP95 had a similar effect, chromatin condensed in mi-
totic extract was purified by sedimentation and further in-
cubated in a fresh extract immunodepleted of AKAP95.
Chromatin exposed to AKAP95-depleted, but not mock-
depleted, extract underwent decondensation within 2 h
(Fig. 6 A), indicating that AKAP95 is implicated in main-
taining chromatin in a condensed form. Moreover, the ex-
tent of chromatin decondensation after immunoblocking
or immunodepletion of AKAP95 was more limited than
decondensation of mitotic chromatin exposed to an in-
terphase extract (Fig. 6 A, Interphase), suggesting the
involvement of distinct decondensation pathways. Con-
sequently, chromatin decondensation in mitotic extract
was referred to as premature chromatin decondensation
(PCD).
As PCD might be interpreted as a consequence of pre-
mature exit of the extract from the M phase, we tested this
possibility by measuring the level of histone H1 kinase ac-
tivity in the mitotic extract incubated for 2 h without or
with anti–AKAP95 antibodies and in AKAP95-depleted
extract. Fig. 6 B shows that elevated (mitotic) levels of H1
kinase activity were maintained in antibody-containing
and immunodepleted extracts (compare with basal H1
kinase activity in interphase HeLa cell extract). This re-
sult indicates that immunoblocking or immunodepleting
AKAP95 did not release the extract from the M phase,
and lends further support to the hypothesis that PCD and
interphase chromatin decondensation involve distinct pro-
cesses.
Conclusive evidence that AKAP95 was required for
maintenance of condensed chromatin in vitro was pro-
vided in a rescue experiment. Purified condensed chroma-
tin was exposed to mitotic extract immunodepleted of
AKAP95. Increasing concentrations of GST-AKAP95D1-
386 were added and after 2 h proportions of PCD were
determined by DNA staining. GST-AKAP95D1-386 dra-
matically inhibited PCD in a concentration-dependent
manner (Fig. 6 C). We determined whether GST-
AKAP95D1-386 was also able to promote recondensation
Figure 5. Injection of anti–AKAP95 antibodies into
HeLa cell nuclei prevents mitotic chromosome conden-
sation but not nuclear membrane disassembly. (A)
Cells were synchronized in S phase by double thymi-
dine block (a, input cells), and nuclei were microin-
jected with z2 pg of either preimmune IgGs (b), affin-
ity-purified anti–AKAP95 polyclonal antibodies (c),
mAb 36 (d), or anti–AKAP95 polyclonal antibodies
with  z250 pg competitor GST-AKAP95D1-386 peptide
(e). In each case, injection solution contained 10 mg/ml
of a 150-kD FITC-dextran (green) to verify injections
into nuclei (a). Subsequently, injected cells were syn-
chronized in metaphase with nocodazole for 18 h and
examined by bright field and fluorescence microscopy (b–e). (B) Mitotic index of cells injected with indicated reagents or control nonin-
jected cells was determined after labeling DNA with Hoechst 33342. (C) Immunofluorescence detection of LBR in noninjected inter-
phase cells, or cells injected with indicated reagents as in A. DNA was labeled with Hoechst 33342. Bars, 10 mm.The Journal of Cell Biology, Volume 147, 1999 1174
of prematurely decondensed chromatin. Purified con-
densed chromatin was allowed to undergo PCD for 2 h in
AKAP95-depleted mitotic extract. Subsequent addition of
GST-AKAP95D1-386 to the extract restored chromatin
condensation also in a concentration-dependent manner
(Fig. 6 D). Thus, GST-AKAP95D1-386 was capable of in-
hibiting PCD and recondensing prematurely decondensed
chromatin in AKAP95-depleted extract, indicating that
AKAP95 is required for maintaining chromatin in a con-
densed form. Furthermore, since anti–AKAP95 antibod-
ies do not block binding of RIIa to AKAP95, the data also
argue that AKAP95 has an intrinsic function in the main-
tenance of condensed chromatin.
The relevance of these in vitro observations on chromo-
some structure during mitosis was investigated. HeLa cells
arrested in the M phase with 1 mM nocodazole were in-
jected with affinity-purified anti–AKAP95 antibodies and,
after 1 h, chromatin morphology was assessed by phase-
contrast and DNA staining while cells remained in no-
codazole. Anti–AKAP95 antibodies readily induced de-
condensation of chromosomes that could no longer be
distinguished by phase-contrast (Fig. 7, a-AKAP95, arrow
points to the metaphase chromosomes of a mitotic cell
that was not injected). Furthermore, no nuclear envelope
was detected, arguing that decondensation was reminis-
cent of PCD observed previously in vitro and distinct from
interphase nuclear reformation. In contrast, coinjection of
anti–AKAP95 antibodies with 250 pg GST-AKAP95D1-
386 did not alter the state of chromosome condensation
(Fig. 7, a-AKAP95 1 pept.). These results indicate that
chromosome decondensation is not an artefactual conse-
quence of exposure of cells to nocodazole. Rather, they
show that as in in vitro, immunoblocking AKAP95 at mi-
tosis induces PCD, indicating that functional AKAP95 is
needed for maintaining chromosomes condensed through-
out mitosis.
Anchoring of RIIa to AKAP95 and PKA Activity Are 
Required for Maintenance of Condensed Chromatin 
during Mitosis
Whether AKAP95–RIIa association and cAMP signaling
through PKA were required for maintenance of con-
densed chromatin during M phase was examined. Purified
condensed chromatin was added to a mitotic extract prein-
cubated with 500 nM Ht31 (or control Ht31-P) peptides to
Table I. Disruption of AKA95-RII Anchoring or cAMP/PKA 
Inhibition Does Not Inhibit Mitotic Chromosome Condensation
Inhibitor Mitotic index
(Percent)
None (z25 pl FITC-dextran) 88 6 8
a-AKAP95 (polyclonal; z2 pg) 17 6 7
a-AKAP95 (z2 pg) 1 GST-AKAP95D1-386 (250 pg) 80 6 6
Ht31 (50 nM) 79 6 8
Ht31-P (50 nM) 82 6 6
PKI (10 nM) 85 6 5
Rp-8-Br-cAMPS (10 mM) 90 6 4
Nuclei of HeLa cells synchronized in interphase were injected with either 2–5 pg af-
finity-purified polyclonal anti–AKAP95 antibodies, 2–5 pg anti–AKAP95 antibodies
with 250 pg GST-AKAP95D1-386 peptide, 50 nM RII-anchoring inhibitor peptide
Ht31, 50 nM control Ht31-P peptide, 10 nM PKI, or 10 mM cAMP antagonist Rp-
8-Br-cAMPS. Injection volumes were 25–50 pl. Control nuclei were injected with
25–50 pl FITC-dextran only. Cells were released from the thymidine block and syn-
chronized with 1 mM nocodazole to induce M phase arrest. After 17 h in nocodazole,
mitotic indexes were determined. Data from 30–50 injected cells per treatment are re-
ported. (Similar results were obtained regardless of the site of injection within the
cells; data not shown).
Figure 6. AKAP95 is required for the maintenance of condensed
chromatin in mitotic extract. (A) Immunoblocking or immunode-
pletion of AKAP95 promotes PCD. Morphology of in vitro–con-
densed chromatin exposed for 2 h to mitotic extract containing
either affinity-purified anti–AKAP95 antibodies (1a-AKAP95),
preimmune IgGs (1IgG), or anti–AKAP95 antibodies with 0.1
mg/ml GST-AKAP95D1-386 competitor peptide (1a-AKAP95 1
GST-AKAP95D1-386). Alternatively, chromatin was also ex-
posed to mitotic extract immuno- or mock-depleted of AKAP95
(AKAP95-depl. and Mock-depl., respectively). Chromatin was
also incubated in interphase extract for 1 h (Interphase). Bar, 10
mm. (B) Histone H1 kinase activity of either mitotic extracts after
2 h of incubation at 308C without (M) or with anti–AKAP95
polyclonal antibodies (M, 1 a-AKAP95), mitotic extract immuno-
depleted of AKAP95 (M, AKAP95-depl.), interphase cytosolic
extract to assess baseline H1 kinase activity (I), or cell lysis buffer
used to prepare the mitotic extracts (Buffer). (C) Inhibition of
PCD with GST-AKAP95D1-386. Purified condensed chromatin
was incubated for 2 h in mitotic extract immunodepleted of
AKAP95 and containing increasing concentrations of GST-
AKAP95D1-386. Proportions of PCD were determined after
DNA staining with Hoechst. (D) Restoration of condensation of
prematurely decondensed chromatin with GST-AKAP95D1-386.
Purified condensed chromatin was allowed to undergo PCD for 2 h
in mitotic extract immunodepleted of AKAP95. Increasing con-
centrations of GST-AKAP95D1-386 were added, and propor-
tions of recondensed chromatin units determined after another
hour of incubation.Collas et al. AKAP95 Function in Chromosome Condensation 1175
disrupt AKAP95–RII interactions (data not shown) and
PCD was assessed after 1 h by DNA staining. Fig. 8 A
shows that while chromatin remained condensed with
Ht31-P, Ht31 induced PCD, indicating a requirement for
AKAP95–RII interaction to maintain chromatin con-
densed. Whether PKA activity and cAMP signaling were
involved in this process was determined using PKA inhibi-
tor PKI (1 mM) and the cAMP antagonist Rp-8-Br-
cAMPS (100 mM). Both reagents induced PCD, whereas
control activation of PKA with 1 mM cAMP had no effect
(Fig. 8 A). Adding free C subunits together with anti–
AKAP95 antibodies also induced PCD (Fig. 8 A), sug-
gesting that only PKA bound to chromatin-associated
AKAP95 is implicated in maintaining condensed chroma-
tin. Altogether, these results indicate that maintenance of
condensed chromatin in mitotic extract requires functional
AKAP95, cAMP signaling events mediated by PKA
and anchoring of PKA (via RIIa) to chromosomes by
AKAP95.
The requirement for RIIa binding to AKAP95 and
PKA activity for maintenance of condensed chromatin
was tested further by assessing chromatin morphology af-
ter immunodepleting RIIa from the extract. Up to 60% of
condensed chromatin masses incubated in the mitotic ex-
tract depleted of RIIa underwent PCD over a 2-h period
(Fig. 8 B). Moreover, immunoblotting analysis of chroma-
tin at the beginning (0 h) and at the end (120 min) of incu-
bation in an RIIa-depleted extract showed that whereas
input chromatin harbored RIIa, most RIIa was solubilized
by 120 min (Fig. 8 C, bottom). In contrast, no obvious
change in the amount of AKAP95 bound to chromatin
was detected under these conditions (Fig. 8 C, top). To-
gether with our previous observation that RIIa is re-
cruited from the cytosol to the chromatin via AKAP95,
these results reflect a dissociation of RIIa from the chro-
matin and suggest that, as with AKAP95, keeping RIIa on
condensed chromatin involves an equilibrium between
soluble and chromatin-associated pools of PKA.
The requirements for AKAP–RII interaction and
cAMP/PKA signaling events to maintain chromosomes
condensed at mitosis were investigated by microinjecting
M phase–arrested HeLa cells with either 50 nM Ht31 or
Ht31-P, 10 nM PKI, 10 mM Rp-8-Br-cAMPS, z1 ng C, or
2–5 pg anti-AKAP95 antibodies together with z1 ng C.
The cells remained exposed to nocodazole for 1 h after in-
jections and were examined by phase-contrast microscopy
and DNA staining. Data of Fig. 9 show that Ht31 (but not
Ht31-P), PKI and Rp-8-Br-cAMPS induced PCD, indicat-
ing that PKA-AKAP anchoring, PKA activity, and cAMP
signaling are required for maintenance of condensed chro-
matin throughout mitosis. Coinjection of anti–AKAP95
antibodies with C also promoted PCD (Fig. 9), arguing
that functional inhibition of AKAP95 promotes chromatin
decondensation even in the presence of unbound PKA.
Immunoblocking of AKAP95 Inhibits Recruitment of 
Eg7 to Chromatin in Mitotic Extract
Several proteins have been shown to be required for mi-
totic chromosome condensation, including pEg7 (Cubi-
zolles et al., 1998), a component of the 13S condensin com-
plex (Hirano et al., 1997). To determine whether AKAP95
was part of the condensin complex or interacted with the
complex, immunoprecipitations were carried out first from
lysates of interphase or mitotic HeLa cells. Immunoblot-
ting analysis of human Eg7 using a polyclonal antibody
Figure 7. Induction of PCD in mitotic HeLa cells by immuno-
blocking of AKAP95. HeLa cells were synchronized in metaphase
by thymidine block and nocodazole treatment. Mitotic cells were
injected with either 2–5 pg affinity-purified polyclonal anti–
AKAP95 antibodies or anti–AKAP95 antibodies together with
250 pg competitor GST-AKAP95D1-386 peptide. Control cells
were injected with FITC-dextran only (top). Cells remained in
nocodazole after injection and were examined after 1 h by phase-
contrast and fluorescence (FITC) microscopy. DNA was labeled
with Hoechst 33342. Percentage of PCD was calculated from 30–
40 cells injected per treatment. Arrow points to a noninjected cell
that did not undergo PCD. Bars, 10 mm.
Figure 8. AKAP95–RIIa interaction, cAMP signaling, and PKA
activity are required for maintenance of condensed chromatin in
mitotic extract. (A) Chromatin condensed in mitotic extract was
purified and exposed to fresh mitotic extract containing either
anti–AKAP95 antibodies (1:50 dilution), 500 nM Ht31, 500 nM
Ht31-P, 1 mM PKI, 100 mM Rp-8-Br-cAMPS, 1 mM cAMP, 15
ng/ml recombinant catalytic subunit of PKA (C), or C plus anti–
AKAP95 antibodies. Proportions (percent 6 SD) of PCD were
determined by DNA labeling after 90 min. (B) Chromatin con-
densed in mitotic extract was purified and exposed to fresh mi-
totic extract immunodepleted of RIIa. Proportions (percent 6
SD) of PCD were determined by DNA staining of sample ali-
quots at regular intervals. (C) Chromatin fractions at the start
(Input) and at the end (120 min) of incubation in RIIa-depleted
mitotic extract were sedimented and proteins were immunoblot-
ted using anti–AKAP95 and anti–RIIa antibodies.The Journal of Cell Biology, Volume 147, 1999 1176
against the 15–carboxy-terminal amino acids of human
Eg7 revealed that interphase and mitotic cells harbored
similar levels of Eg7 (Fig. 10 A). Immunoprecipitation
data showed that AKAP95 and Eg7 did not coprecipitate
from interphase cell lysates, indicating that these proteins
do not interact at this stage of the cell cycle (Fig. 10 B). In
contrast, in mitotic cell lysates, AKAP95 and Eg7 copre-
cipitated regardless of the antibody used (Fig. 10 C), sug-
gesting that AKAP95 and Eg7 interact at mitosis. Since
AKAP95 was found to be associated with chromatin at
mitosis (Fig. 1 C), we tested the possibility that the
AKAP95–Eg7 interaction was mediated by DNA. To this
end, mitotic chromatin was isolated, solubilized with
micrococcal nuclease, and the DNA was digested with
400 mg/ml DNase I in the presence of protease inhibi-
tors. Immunoprecipitation of AKAP95 or Eg7 from the
DNase-treated fraction revealed that both proteins also
coprecipitated (Fig. 10 D), suggesting that the mitotic
AKAP95–Eg7 interaction is not mediated by DNA and is
probably direct.
pEg7, the Xenopus homologue of human Eg7, has been
previously shown to be recruited onto condensing chro-
mosomes at mitosis (Cubizolles et al., 1998). Results from
our laboratory have shown that chromatin condensation in
the mitotic extract is accompanied by association of Eg7
with chromatin (Landsverk, H., K.L. Guellec, and P. Col-
las, unpublished observation). Since pEg7 is required for
chromosome condensation, we determined whether im-
munoblocking nuclear AKAP95 would affect the recruit-
ment of Eg7 to chromatin in vitro. Nuclei loaded with pre-
immune IgGs (2a-AKAP95) or anti–AKAP95 antibodies
(1a-AKAP95) were allowed to condense for 2 h in mi-
totic extract. Chromatin masses were sedimented and im-
munoblotted using anti–Eg7 antibodies. As expected from
our previous results anti–AKAP95 antibodies blocked
chromatin condensation. Remarkably, the antibodies also
prevented the recruitment of Eg7 to chromatin (Fig. 10 E,
1a-AKAP95) that normally occurs in extract either in the
absence of antibodies (not shown) or with nuclei loaded
with preimmune IgGs (Fig. 10 D, 2a-AKAP95). Loading
nuclei with anti–HP1a antibodies did not impede associa-
tion of Eg7 with chromatin (Fig. 10 E, 1a-HP1a), indicat-
ing that inhibition of Eg7 recruitment by anti–AKAP95
antibodies is not a mere consequence of steric hindrance
imposed by the antibody. Altogether, these results suggest
that functional inhibition of AKAP95 prevents the associ-
ation of Eg7 to chromatin required for condensation.
Discussion
This paper provides evidence that AKAP95 is a multiva-
lent protein with a role in chromosome condensation at
mitosis. AKAP95 acts as an anchor for a PKA-signaling
complex onto mitotic chromosomes, which is required
for maintenance of chromosomes in a condensed form
throughout mitosis. AKAP95 also appears essential for
the recruitment onto chromosomes of Eg7, a component
Figure 9. Disruption of AKAP95–RII interaction and downregu-
lation of cAMP/PKA signaling promote PCD in mitotic cells. Mi-
totic HeLa cells were injected as in Fig. 7 with either 50 nM RII-
anchoring inhibitor peptide Ht31, 50 nM control Ht31-P, 10 nM
PKI, 10 mM cAMP antagonist Rp-8-Br-cAMPS, z1 ng C, or z1
ng C together with 2–5 pg anti–AKAP95 antibodies. Cells re-
mained in nocodazole after injection and were examined as in
Fig. 7. Percentage of PCD was calculated from 30–40 injected
cells. Bars, 10 mm.
Figure 10. Immunoblocking of AKAP95 inhibits the association
of Eg7 to condensed chromatin in mitotic extract. (A) Immuno-
blot of interphase (I) and mitotic (M) HeLa cell lysates with anti-
bodies against Eg7, a component of the human condensin com-
plex. (B) AKAP95 and Eg7 were immunoprecipitated from
interphase HeLa cell lysates and precipitates were immunoblot-
ted with each precipitating antibody. (C) AKAP95 and Eg7 were
immunoprecipitated from mitotic HeLa cell lysates and precipi-
tates immunoblotted as in B. (D) AKAP95 and Eg7 were immu-
noprecipitated from mitotic chromatin after solubilization with
micrococcal nuclease and digestion with DNase I. Precipitates
were immunoblotted as in B. (B–D) Control immunoprecipita-
tions were carried out with preimmune rabbit IgGs (IgG).
(E) Interphase nuclei (N) loaded with preimmune IgGs
(2a-AKAP95), anti–AKAP95 antibodies (1a-AKAP95) or
anti–HP1a antibodies (1a-HP1a) were allowed to condense in
mitotic extract. After 2 h, chromatin masses (Ch) were sedi-
mented and immunoblotted using anti–Eg7 antibodies.Collas et al. AKAP95 Function in Chromosome Condensation 1177
of the condensin complex. The data also provide insights
on the significance of the rise in cAMP level and PKA ac-
tivity during mitosis.
Several lines of evidence illustrate a function of
AKAP95 in chromosome condensation and maintenance
of chromosomes in a condensed form during mitosis. First,
immunoblocking intranuclear AKAP95 inhibits chromatin
condensation in vitro and in vivo. Second, immunoblock-
ing AKAP95 during mitosis or in vitro, or immunodeple-
tion of soluble AKAP95 from the mitotic extract, induces
PCD. Inhibition of chromatin condensation with anti–
AKAP95 antibodies is unlikely to result from a nonspe-
cific steric effect of the antibodies since antibodies against
all variants of the heterochromatin protein HP1 (Minc et al.,
1999) are ineffective. Clearly, AKAP95 is implicated in
chromatin condensation before PKA associates with chro-
matin and interacts with AKAP95. This is consistent with
the established downregulation of PKA required for mi-
totic nuclear envelope breakdown (Lamb et al., 1991) and
with the absence of PKA in interphase nuclei (Eide et al.,
1998). Thus, in principle, AKAP95 and RII cannot interact
until the nuclear envelope has broken down. However,
once nuclear envelope disassembly has occurred, the role
of AKAP95 in maintaining condensed chromosomes re-
quires cAMP/PKA signaling and AKAP95–PKA interac-
tion.
A third observation supporting the involvement of
AKAP95 in regulating chromosome structure at mitosis is
the finding that a recombinant AKAP95 fragment (GST-
AKAP95D1-386) prevents PCD in AKAP95-depleted ex-
tract, and restores condensation of prematurely decon-
densed chromatin, both in a dose-dependent manner.
Thus, the domain(s) of AKAP95 required for this activity
and for interaction of AKAP95 with chromatin reside(s)
in the carboxy-terminal 306 amino acids (amino acids 387–
692) of the protein. As expected from the RII binding re-
quirement for maintenance of condensed chromatin, this
AKAP95 fragment also contains the RII binding motif
(Eide et al., 1998).
The consequences of immunoblocking AKAP95 may be
accounted for by the hypothesis that AKAP95 function
may be disrupted by antibodies only when they bind
AKAP95 that is not associated with chromatin. Indeed,
the antibodies block condensation when incorporated into
interphase nuclei before association of AKAP95 with
chromatin (Landsverk, H., and P. Collas, unpublished re-
sults). Thus, it is possible that anti–AKAP95 antibodies in-
cubated in mitotic cytosol fail to inhibit chromatin conden-
sation because by the time the nuclear envelope breaks
down, nuclear AKAP95 has already associated with chro-
mosomes. Similarly, induction of PCD in cytosol immu-
nodepleted of AKAP95 suggests that the establishment of
an equilibrium between chromosome-associated and solu-
ble AKAP95 is critical for maintenance of condensation.
By binding AKAP95 when it dissociates from chromo-
somes as well as soluble AKAP95, the antibodies may
sharply decrease the on-rate of AKAP95 to chromosomes,
causing decondensation of the chromatin.
Since it associates with chromatin early during mitotic
nuclear disassembly, AKAP95 could conceivably either di-
rectly affect chromatin structure, or facilitate the recruit-
ment of factors controlling mitotic chromosome condensa-
tion (Hirano and Mitchison, 1994; Hirano et al., 1997).
Sequence analysis of human AKAP95 (Eide et al., 1998)
reveals that AKAP95 is unlikely to belong to the family of
SMC proteins, factors shown to affect chromosome struc-
ture at mitosis and during development (Strunnikov,
1998). Unlike SMC proteins, AKAP95 displays no coiled-
coil domains, no amino-terminal ATP-binding sites and no
DA box, a signature motif of SMCs (Strunnikov et al.,
1993). Likewise, AKAP95 displays no consensus site for
topoisomerase II (Adachi et al., 1991); thus, unlike SMCs
or topoisomerase II, AKAP95 is probably unlikely to di-
rectly impose a conformational change on chromatin in-
ducing condensation. Rather, our data suggest that a func-
tion of AKAP95 is to allow the recruitment of components
of the condensin complex. First, immunoblocking of
AKAP95 inhibits association of Eg7 with chromatin in
vitro. Eg7 is the human homologue of Xenopus pEg7,
a protein associated with the 13S condensin complex
(Hirano and Mitchison, 1994; Cubizolles et al., 1998), sug-
gesting that anti–AKAP95 antibodies prevent binding
of the condensin complex onto chromosomes. Second,
AKAP95 can be coprecipitated with Eg7 from solubilized,
DNase-digested mitotic chromatin, suggestive of an inter-
action between AKAP95 and Eg7 that is not mediated by
DNA. Collectively, these findings raise the attractive pos-
sibility that one function of AKAP95 is to facilitate re-
cruitment and/or anchoring of condensins to chromatin at
mitosis.
The multivalent nature of AKAP95 is not only evi-
denced by its role in chromatin condensation, but also by
the observation that AKAP95 maintains a crucial PKA-
anchoring function during mitosis. Whereas AKAP95 and
RII are found in a different compartment in interphase,
a chromosome-associated AKAP95–PKA signaling com-
plex is established at mitosis. Induction of PCD after im-
munodepletion of RIIa from mitotic cytosol reflects an
equilibrium between chromatin-associated (via AKAP95)
and soluble RIIa, and a requirement for a soluble pool of
RIIa to maintain the chromatin fraction of the AKAP95–
RIIa complex saturated and functional. Disruption of
PKA anchoring with Ht31 peptides induces PCD in vitro
and in vivo, indicating that the AKAP95–PKA interaction
is essential for the maintenance of condensed chroma-
tin. Several physiological functions implicating AKAP-
anchored PKA have been reported using similar disrup-
tion approaches (Colledge and Scott, 1999). Formation of
the AKAP95–PKA complex early during chromosome
condensation may be critical to mediate the increasing
cAMP signal as mitosis progresses (Grieco et al., 1996). It
is conceivable that maintenance of a condensed chromatin
structure results from PKA-dependent phosphorylation of
chromatin substrates such as histones (Van Hooser et al.,
1998; Wei et al., 1999) or other DNA-related structural
regulators such as topoisomerases (Roberge et al., 1990).
Our results provide some significance for the rising level
of cAMP and increasing PKA activity during mitosis
(Grieco et al., 1996). Implications of PKA downregulation
in entry into mitosis have been addressed previously
(Lamb et al., 1991). It has been reported that cAMP levels
and PKA(2type II) activity are significant (Costa et al.,
1976) or even rise (Grieco et al., 1996) during mitosis. We
propose that rising cAMP levels during mitosis activateThe Journal of Cell Biology, Volume 147, 1999 1178
chromatin-associated PKA, which together with AKAP95,
is required to ensure proper chromosome condensation
throughout mitosis. This view is supported by the induc-
tion of PCD by cAMP antagonists or PKI. Moreover,
anti–AKAP95 antibodies added to cytosol in vitro or in
vivo together with free PKA C subunit also promote PCD.
Since cytosolic anti–AKAP95 antibodies presumably in-
hibit binding of soluble AKAP95 to chromatin, the latter
observation argues that only C bound to chromosomes
is relevant for maintenance of condensed chromatin,
whereas free cytosolic C is ineffective. Higher PKA activ-
ity at the end of mitosis facilitates chromatin decondensa-
tion and nuclear reassembly (Grieco et al., 1996). This sce-
nario implies the induction of antagonistic effects of
cAMP/PKA signaling on chromosome structure at mitosis
that are temporally distinct. It also implicates the existence
of a molecular switch upstream of the cAMP/PKA path-
way, that controls the dual effect of cAMP/PKA activity at
mitosis. A likely candidate might be M phase–promoting
factor, as a threshold level of this activity has been shown
to be required to initiate activation of the cAMP/PKA
pathway during mitosis (Grieco et al., 1996). The dual ef-
fect of PKA during mitosis and at the exit of mitosis could
also be due to the redistribution of AKAP95, which disso-
ciates from PKA at mitosis exit.
Although the structural determinants mediating AKAP–
RII interactions in general are being characterized (Col-
ledge and Scott, 1999), whether additional processes
modulate these associations is unknown. Circumstantial
evidence suggests the involvement of posttranslational
modification of RII in such regulation. First, RIIa is pri-
marily localized in the centrosome–Golgi area (Keryer et al.,
1998) in interphase HeLa cells, presumably via a centroso-
mal AKAP (Witczak et al., 1999). Release of RIIa from
centrosomes at mitosis correlates with CDK1-mediated
phosphorylation of RIIa (Keryer et al., 1998). Second,
CDK1-mediated phosphorylation of RIIa in vitro is suffi-
cient to induce partial solubilization of RIIa from a Triton
X-100 insoluble pool (Keryer et al., 1998). Third, associa-
tion of AKAP95 with RIIa is mitosis-specific. Finally,
decondensation of in vitro–condensed chromatin in an
interphase extract is associated with release of RIIa
from chromatin-associated AKAP95 (Collas, P., data not
shown). This argues that binding of RIIa to AKAP95 at
mitosis is not a mere consequence of both proteins being
in the same subcellular compartment; rather, a modifica-
tion of either protein seems to affect their interaction. To-
gether with the data of Keryer et al. (1998), our results ar-
gue for a cell cycle–regulated redistribution of RIIa,
suggesting an additional mechanism regulating PKA type
II subcellular localization.
An emerging feature of AKAPs is their ability to anchor
entire signaling complexes other than PKA to specific sub-
strates. To date, AKAP79, AKAP220, gravin, yotiao/
AKAP450/CG-NAP, and ezrin have been shown to act as
polyvalent anchoring proteins for signaling units involving
PKA or protein kinase C together with protein phos-
phatases (Colledge and Scott, 1999). Additional binding
partners of AKAP95 besides PKA at mitosis have yet to
be identified. Nevertheless, our results extend the concept
that AKAP95 is likely to be a multivalent targeting mole-
cule anchoring signaling complexes as well as chromatin
remodeling factors in a cell cycle–regulated manner. It will
be exciting to determine whether additional AKAPs also
harbor specific intrinsic cellular functions.
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